A bill making its way through the German legislative system could make it easier for hospitals to secure financing for cell and gene therapies. The Alliance for Regenerative Medicine (ARM) has welcomed the move and says it will “reduce a bureaucratic hurdle that stood in the way of patient access to durable and potentially curative" advanced therapy medicinal products.
The changes will apply to the NUB (new diagnostic and treatment methods) pathway, which finances the costs of new treatments...